2020
Polypharmacy and frailty among persons with HIV
Sung M, Gordon K, Edelman EJ, Akgün KM, Oursler KK, Justice AC. Polypharmacy and frailty among persons with HIV. AIDS Care 2020, 33: 1492-1499. PMID: 32880183, PMCID: PMC7925692, DOI: 10.1080/09540121.2020.1813872.Peer-Reviewed Original ResearchConceptsNon-ARV medicationsVeterans Aging Cohort StudyFrailty-related phenotypeLow physical activityAging Cohort StudyCross-sectional studyWarrants further studyUninfected participantsAntiretroviral therapyCohort studyRefill dataAdjusted analysisViral loadPolypharmacyPhysical activityGeneral populationMedicationsPLWHFrailtyStrong associationFurther studiesHIVPrimary predictorAssociationLarge proportion
2019
Differentiating Types of Self-Reported Alcohol Abstinence
Gordon KS, McGinnis K, Dao C, Rentsch CT, Small A, Smith RV, Kember RL, Gelernter J, Kranzler HR, Bryant KJ, Tate JP, Justice AC. Differentiating Types of Self-Reported Alcohol Abstinence. AIDS And Behavior 2019, 24: 655-665. PMID: 31435887, PMCID: PMC6994373, DOI: 10.1007/s10461-019-02638-x.Peer-Reviewed Original ResearchConceptsLifetime abstainersSelf-reported alcohol abstinenceAlcohol biomarkersGenetic polymorphismsLogistic regression modelsHepatitis CAlcohol abstinenceUninfected individualsCharacteristics of peopleAlcohol useAbstinenceHealth effectsSmokingAbstainersBiomarkersRegression modelsOddsAssociationPLWHPolymorphismHIVCocaine
2018
Nonantiretroviral polypharmacy and adverse health outcomes among HIV-infected and uninfected individuals
Justice AC, Gordon KS, Skanderson M, Edelman EJ, Akgün KM, Gibert CL, Re V, Rimland D, Womack JA, Wyatt CM, Tate JP, Team V. Nonantiretroviral polypharmacy and adverse health outcomes among HIV-infected and uninfected individuals. AIDS 2018, 32: 739-749. PMID: 29543653, PMCID: PMC5868488, DOI: 10.1097/qad.0000000000001756.Peer-Reviewed Original ResearchConceptsAdverse health outcomesHIV statusUninfected individualsVACS IndexMedication countUS Veterans Affairs Healthcare SystemHealth outcomesVeterans Affairs Healthcare SystemRisk of hospitalizationSeverity of illnessHIV-1 RNAHIV-positive individualsRisk of mortalityDose responseRace/ethnicityPolypharmacyFiscal year 2009HospitalizationMedicationsMortalityHealthcare systemAntiretroviralsOutcomesAssociationRisk
2012
Patient-Reported Symptoms on the Antiretroviral Regimen Efavirenz/Emtricitabine/Tenofovir
Edelman EJ, Gordon K, Rodriguez-Barradas MC, Justice F. Patient-Reported Symptoms on the Antiretroviral Regimen Efavirenz/Emtricitabine/Tenofovir. AIDS Patient Care And STDs 2012, 26: 312-319. PMID: 22612469, PMCID: PMC3412583, DOI: 10.1089/apc.2012.0044.Peer-Reviewed Original ResearchMeSH KeywordsAdenineAlkynesAnti-HIV AgentsBenzoxazinesCohort StudiesCross-Sectional StudiesCyclopropanesDeoxycytidineDrug Therapy, CombinationEmtricitabineFemaleHealth StatusHIV InfectionsHumansMaleMiddle AgedOrganophosphonatesQuality of LifeSeverity of Illness IndexTenofovirTreatment OutcomeVeteransConceptsEFV/FTC/TDFCombination antiretroviral therapyFTC/TDFHealth-related qualityTDF useSymptom experienceEfavirenz/emtricitabine/tenofovirVeterans Aging Cohort StudyPatient-reported symptomsAging Cohort StudyEmtricitabine/tenofovirCross-sectional analysisAntiretroviral therapyCohort studyMost patientsPatient tolerabilitySymptom burdenTreatment characteristicsPatientsDisease severityAnalytic sampleTenofovirSymptomsTDFAssociation